6SEPTEMBER - 2020TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comDespite the promises of a better life, traditional cancer treatments like chemotherapy and radiation often fall short in delivering adequate relief. Today, people are seeking personalized cancer treatment options that provide a higher chance of recovery. In this regard, several immunotherapies are now being offered to patients to identify effective person-specific treatment options. To that end, many new and promising technology trends are being observed in the immuno-oncology therapeutic space. Technologies like AI and machine learning are offering a way to generate a database of cancer patients and their immune responses for future candidates with similar genetic profiles. Besides, the popularity and proven benefits of connected devices are paving new routes in immuno response imaging without radiation exposure.In this edition of Pharma Tech Outlook, we present to you the story of Oncolytics Biotech. This company is developing an intravenously delivered immuno-oncolytic virus called "pelareorep" to treat solid tumors and hematological malignancies. This edition brings you some of the most prominent organizations specializing in the immunotherapy landscape that are driving the key trends and strategies. Besides, the magazine also offers a combination of thought leadership from subject-matter experts with real-life stories and exclusive insights from CIOs and CXOs. We hope this edition will provide you with the right assistance in choosing the immunotherapy companies according to your requirements. Let us know your thoughts!Beyond the Initial Threshold of ImmunotherapyCopyright © 2020 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.SEPTEMBER - 14 - 2020, Vol 06 - Issue 19 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405Jaxon JaseTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >